Table 2.
Molecular profiling’s characteristics.
| F1LCDx’s Characteristics | Overall Population n = 180 |
AMA n = 100 (52%) |
Non-AMA n = 80 (42%) |
p-Value * |
|---|---|---|---|---|
| Result Delay | 0.56 | |||
| Median, days (range) | 13 (5–38) | 13 (5–28) | 13 (7–27) | |
| Timing of F1LCDx testing | 0.0004 | |||
| Progression on non-TT | 109 (61%) | 74 (74%) | 35 (44%) | |
| During treatment | 44 (24%) | 16 (16%) | 28 (35%) | |
| Progression on TT | 11 (6%) | 6 (6%) | 5 (6%) | |
| Diagnosis | 7 (4%) | 1 (1%) | 6 (7%) | |
| Metastatic relapse | 6 (3%) | 2 (2%) | 4 (5%) | |
| Other | 3 (2%) | 1 (1%) | 2 (3%) | |
| Previous Molecular Profile | ||||
| n (%) | 147 (82%) | 83 (83%) | 64 (80%) | - |
| with previous MA | 99/147 (67%) | 60/83 (72%) | 39/64 (61%) | 0.7 |
| with previous AMA | 53/147 (36%) | 38/83 (46%) | 15/64 (23%) | 0.16 |
| Tumor Fraction (%) | 0.91 | |||
| Median (range) | 21 (10–72) | 21 (10–72) | 19 (11–71) | |
| Tumor Mutational Burden | 0.01 | |||
| <10 mut/Mb | 84 (47%) | 43 (43%) | 41 (51%) | |
| ≥10 mut/Mb | 12 (6%) | 11 (11%) | 1 (1%) | |
| Missing | 84 (47%) | 46 (46%) | 38 (48%) | |
| MSI status | 0.35 | |||
| MSI high | 1 (1%) | 1 (1%) | 0 | |
| MSI high not detected | 28 (15%) | 13 (13%) | 15 (19%) | |
| Undetermined | 151 (84%) | 86 (86%) | 65 (81%) |
AMA: actionable molecular alteration; F1LCDx: FoundationOne Liquid CDx; MA: molecular alteration; MMT: molecularly matched therapy; TT: targeted therapy. * p-value is provided for comparison between groups: “AMA” vs. “non-AMA”.